Department of Medicine, Zucker School of Medicine at Hofstra, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, NY 11030, United States.
Preclinical Studies, New York Institute of Technology College of Osteopathic Medicine, Glen Head, NY 11545, United States.
World J Gastroenterol. 2024 Jul 7;30(25):3182-3184. doi: 10.3748/wjg.v30.i25.3182.
Inflammatory bowel disease (IBD) is entering a potentially new era of combined therapeutics. Triantafillidis provide an insightful review of the current state of combination therapy, with a focus on the use of a combined biologic and immunomodulator, as well as emerging data on the future potential of dual-biologic therapy (DBT). While current evidence for DBT is limited, encouraging safety profiles and ongoing trials suggest a brighter future for this approach. The importance of controlled trials should be stressed in establishing new treatment paradigms. Ongoing prospective randomized trials of DBT and perhaps future combinations of biologics and small molecule therapies will hopefully guide the next generation of IBD care.
炎症性肠病（IBD）正进入联合治疗的潜在新时代。Triantafillidis 对联合治疗的现状进行了深入的回顾，重点介绍了联合使用生物制剂和免疫调节剂，以及双生物制剂治疗（DBT）未来潜在的数据。虽然目前 DBT 的证据有限，但令人鼓舞的安全性数据和正在进行的试验表明，这种方法的前景更加光明。在建立新的治疗模式时，应强调对照试验的重要性。正在进行的 DBT 的前瞻性随机试验，以及未来生物制剂和小分子治疗的联合试验，有望为 IBD 的下一代治疗提供指导。
